• M Ángeles Ocaña Gómez, Alejandro Ferrer Machín, Martín Vera Cabrera, Karen Ilenia Álvarez Tosco, Mario Ríos de Paz, and M Dolores de Dios García.
• Servicio de Farmacia Hospitalaria, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España.
• Med Clin (Barc). 2024 Feb 9; 162 (3): 134137134-137.

IntroductionEmicizumab is the first non-replacement therapy for prophylaxis in severe hemophilia A.AimsThe principal aim of this study is to describe the results of our patients in prophylaxis with emicizumab, according to the usual clinical practice.Material And MethodsFollow-up of 13 patients from the start of prophylaxis, recording of bleeding, surgeries, adverse reactions and the need or not for factor therapy. Plasma levels were measured at follow-up visits, the technique was coagulative in one stage, modified by 1:20 dilution.ResultsMedian plasma levels were 52.2mg [30.7-71.9]. Prophylaxis was safe and effective; only one spontaneous haemorrhage was recorded over time and no treatment was required. There were no thromboembolic events or serious hypersensitivity, anaphylaxis or anaphylactoid reactions. The incidence of injection site reactions was 8%. Perioperative management in minor interventions was carried out without adjuvant factorial therapy, in 2 major surgeries a dose of plasmatic FVIII concentrate was required in the patient with hemophilia A without inhibitor and FVII in the patient with inhibitor, and it was sufficient to stop the bleeding.ConclusionThis study demonstrated emicizumab pharmacokinetics and its half life ensure optimal levels with prophylaxis treatment at doses established in the technical data sheet.Copyright © 2023 Elsevier España, S.L.U. All rights reserved.

22 keywords...

hide…